The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market was valued at US$ 596 million in 2025 and is anticipated to reach US$ 1007 million by 2032, at a CAGR of 7.9% from 2026 to 2032.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs refer to a class of medications used to treat Paroxysmal Nocturnal Hemoglobinuria, a rare, life-threatening blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. These drugs primarily work by inhibiting the complement system, an immune response that, when overactive in PNH patients, leads to the destruction of red blood cells. Treatments like eculizumab and ravulizumab are commonly used PNH drugs, helping to reduce hemolysis (red blood cell breakdown), manage symptoms, and improve patients' quality of life.

The Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs market is experiencing significant growth, driven by the rising prevalence of the disease and increasing awareness. The market size is expanding, with North America, particularly the U.S., and Europe being the major sales regions due to advanced healthcare infrastructure and higher diagnosis rates. Emerging markets in Asia-Pacific present significant opportunities due to a growing healthcare sector and rising patient awareness. However, challenges such as high treatment costs and limited access to advanced therapies in developing regions persist. Future product development trends focus on improving efficacy, reducing treatment frequency, and introducing cost-effective biosimilars, potentially expanding access to underserved populations.

This report delivers a comprehensive overview of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs. The Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market size, estimates, and forecasts are provided in terms of sales volume (Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Report

Report Metric	Details
Report Name	Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market
Accounted market size in 2025	US$ 596 million
Forecasted market size in 2032	US$ 1007 million
CAGR	7.9%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Oral Drugs Injectable Drugs
by Application	Pharmaceutical and Biotechnology Companies Clinical Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	AstraZeneca, Alexion, Novartis, Apellis Pharmaceuticals, Roche, Amgen, NovelMed, Chugai Pharmaceutical, Akari Therapeutics, Omeros Corporation, Regeneron Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market growing?

Ans: The Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market witnessing a CAGR of 7.9% during the forecast period 2026-2032.

What is the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market size in 2032?

Ans: The Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market size in 2032 will be US$ 1007 million.

Who are the main players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market report?

Ans: The main players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market are AstraZeneca, Alexion, Novartis, Apellis Pharmaceuticals, Roche, Amgen, NovelMed, Chugai Pharmaceutical, Akari Therapeutics, Omeros Corporation, Regeneron Pharmaceuticals

What are the Application segmentation covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market report?

Ans: The Applications covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market report are Pharmaceutical and Biotechnology Companies, Clinical, Others

What are the Type segmentation covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market report?

Ans: The Types covered in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market report are Oral Drugs, Injectable Drugs

1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Overview

1.1 Product Definition

1.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Type

1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Value by Type: 2025 vs 2032

1.2.2 Oral Drugs

1.2.3 Injectable Drugs

1.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Application

1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Value by Application: 2025 vs 2032

1.3.2 Pharmaceutical and Biotechnology Companies

1.3.3 Clinical

1.3.4 Others

1.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Estimates and Forecasts

1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021–2032

1.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021–2032

1.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Competition by Manufacturers

2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Manufacturers (2021–2026)

2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Product Types and Applications

2.7 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Date of Entry into the Industry

2.8 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Competitive Situation and Trends

2.8.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Players Market Share by Revenue

2.8.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Scenario by Region

3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2021–2032

3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2021–2026

3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region: 2027–2032

3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region: 2021–2032

3.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region: 2021–2026

3.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region: 2027–2032

3.4 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Facts & Figures by Country

3.4.1 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021–2032)

3.4.3 North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Facts & Figures by Country

3.5.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021–2032)

3.5.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021–2032)

3.6.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Facts & Figures by Country

3.7.1 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021–2032)

3.7.3 Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021–2032)

3.8.3 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021–2032)

4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021–2026)

4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2027–2032)

4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021–2032)

4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2021–2032)

4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2021–2026)

4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2027–2032)

4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2021–2032)

4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price by Type (2021–2032)

5 Segment by Application

5.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021–2032)

5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021–2026)

5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2027–2032)

5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021–2032)

5.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2021–2032)

5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2021–2026)

5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2027–2032)

5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application (2021–2032)

5.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price by Application (2021–2032)

6 Key Companies Profiled

6.1 AstraZeneca

6.1.1 AstraZeneca Company Information

6.1.2 AstraZeneca Description and Business Overview

6.1.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.1.5 AstraZeneca Recent Developments/Updates

6.2 Alexion

6.2.1 Alexion Company Information

6.2.2 Alexion Description and Business Overview

6.2.3 Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.2.5 Alexion Recent Developments/Updates

6.3 Novartis

6.3.1 Novartis Company Information

6.3.2 Novartis Description and Business Overview

6.3.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.3.5 Novartis Recent Developments/Updates

6.4 Apellis Pharmaceuticals

6.4.1 Apellis Pharmaceuticals Company Information

6.4.2 Apellis Pharmaceuticals Description and Business Overview

6.4.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.4.5 Apellis Pharmaceuticals Recent Developments/Updates

6.5 Roche

6.5.1 Roche Company Information

6.5.2 Roche Description and Business Overview

6.5.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.5.5 Roche Recent Developments/Updates

6.6 Amgen

6.6.1 Amgen Company Information

6.6.2 Amgen Description and Business Overview

6.6.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.6.5 Amgen Recent Developments/Updates

6.7 NovelMed

6.7.1 NovelMed Company Information

6.7.2 NovelMed Description and Business Overview

6.7.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.7.5 NovelMed Recent Developments/Updates

6.8 Chugai Pharmaceutical

6.8.1 Chugai Pharmaceutical Company Information

6.8.2 Chugai Pharmaceutical Description and Business Overview

6.8.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.8.5 Chugai Pharmaceutical Recent Developments/Updates

6.9 Akari Therapeutics

6.9.1 Akari Therapeutics Company Information

6.9.2 Akari Therapeutics Description and Business Overview

6.9.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.9.5 Akari Therapeutics Recent Developments/Updates

6.10 Omeros Corporation

6.10.1 Omeros Corporation Company Information

6.10.2 Omeros Corporation Description and Business Overview

6.10.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.10.5 Omeros Corporation Recent Developments/Updates

6.11 Regeneron Pharmaceuticals

6.11.1 Regeneron Pharmaceuticals Company Information

6.11.2 Regeneron Pharmaceuticals Description and Business Overview

6.11.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolio

6.11.5 Regeneron Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Chain Analysis

7.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Production Mode & Process Analysis

7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales and Marketing

7.4.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Channels

7.4.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors

7.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customer Analysis

8 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Dynamics

8.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Trends

8.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Drivers

8.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Challenges

8.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Alexion

Novartis

Apellis Pharmaceuticals

Roche

Amgen Inc

Chugai Pharmaceutical

Akari Therapeutics

Omeros Corporation

Regeneron Pharmaceuticals

NovelMed

List of Tables

Table 1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Competitive Situation by Manufacturers in 2025

Table 4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units) of Key Manufacturers (2021–2026)

Table 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Manufacturers (2021–2026)

Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Product Types and Applications

Table 12. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (Units), 2021–2026

Table 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2021–2026)

Table 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (Units), 2027–2032

Table 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2027–2032)

Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (US$ Million), 2021–2026

Table 22. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Region (2021–2026)

Table 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (US$ Million), 2027–2032

Table 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Region (2027–2032)

Table 25. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2021–2026

Table 27. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2027–2032

Table 28. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2021–2026

Table 29. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2027–2032

Table 30. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2021–2026

Table 32. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2027–2032

Table 33. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2021–2026

Table 34. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (Units), 2021–2026

Table 37. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (Units), 2027–2032

Table 38. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2021–2026

Table 42. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2027–2032

Table 43. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2021–2026

Table 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (Units), 2027–2032

Table 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (US$ Million), 2027–2032

Table 50. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units) by Type (2021–2026)

Table 51. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units) by Type (2027–2032)

Table 52. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021–2026)

Table 53. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2027–2032)

Table 54. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (US$ Million) by Type (2021–2026)

Table 55. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (US$ Million) by Type (2027–2032)

Table 56. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2021–2026)

Table 57. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2027–2032)

Table 58. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price (US$/Unit) by Type (2021–2026)

Table 59. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price (US$/Unit) by Type (2027–2032)

Table 60. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units) by Application (2021–2026)

Table 61. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units) by Application (2027–2032)

Table 62. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021–2026)

Table 63. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2027–2032)

Table 64. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (US$ Million) by Application (2021–2026)

Table 65. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue (US$ Million) by Application (2027–2032)

Table 66. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application (2021–2026)

Table 67. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application (2027–2032)

Table 68. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price (US$/Unit) by Application (2021–2026)

Table 69. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price (US$/Unit) by Application (2027–2032)

Table 70. AstraZeneca Company Information

Table 71. AstraZeneca Description and Business Overview

Table 72. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 73. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 74. AstraZeneca Recent Developments/Updates

Table 75. Alexion Company Information

Table 76. Alexion Description and Business Overview

Table 77. Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 78. Alexion Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 79. Alexion Recent Developments/Updates

Table 80. Novartis Company Information

Table 81. Novartis Description and Business Overview

Table 82. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 83. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 84. Novartis Recent Developments/Updates

Table 85. Apellis Pharmaceuticals Company Information

Table 86. Apellis Pharmaceuticals Description and Business Overview

Table 87. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 88. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 89. Apellis Pharmaceuticals Recent Developments/Updates

Table 90. Roche Company Information

Table 91. Roche Description and Business Overview

Table 92. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 93. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 94. Roche Recent Developments/Updates

Table 95. Amgen Company Information

Table 96. Amgen Description and Business Overview

Table 97. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 98. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 99. Amgen Recent Developments/Updates

Table 100. NovelMed Company Information

Table 101. NovelMed Description and Business Overview

Table 102. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 103. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 104. NovelMed Recent Developments/Updates

Table 105. Chugai Pharmaceutical Company Information

Table 106. Chugai Pharmaceutical Description and Business Overview

Table 107. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 108. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 109. Chugai Pharmaceutical Recent Developments/Updates

Table 110. Akari Therapeutics Company Information

Table 111. Akari Therapeutics Description and Business Overview

Table 112. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 113. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 114. Akari Therapeutics Recent Developments/Updates

Table 115. Omeros Corporation Company Information

Table 116. Omeros Corporation Description and Business Overview

Table 117. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 118. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 119. Omeros Corporation Recent Developments/Updates

Table 120. Regeneron Pharmaceuticals Company Information

Table 121. Regeneron Pharmaceuticals Description and Business Overview

Table 122. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 123. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product

Table 124. Regeneron Pharmaceuticals Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors List

Table 128. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customers List

Table 129. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Trends

Table 130. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Drivers

Table 131. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Challenges

Table 132. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs

Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Share by Type: 2025 & 2032

Figure 4. Oral Drugs Product Picture

Figure 5. Injectable Drugs Product Picture

Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Value by Application (US$ Million), 2021–2032

Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Share by Application: 2025 & 2032

Figure 8. Pharmaceutical and Biotechnology Companies

Figure 9. Clinical

Figure 10. Others

Figure 11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size (US$ Million), 2021–2032

Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (Units), 2021–2032

Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Average Price (US$/Unit), 2021–2032

Figure 15. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Report Years Considered

Figure 16. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Share by Manufacturers in 2025

Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Share by Manufacturers in 2025

Figure 18. Top 5 and Top 10 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Players: Market Share by Revenue in Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2025

Figure 19. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 21. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021–2032)

Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021–2032)

Figure 23. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 24. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 25. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021–2032)

Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021–2032)

Figure 27. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 28. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 29. U.K. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 30. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2021–2032)

Figure 33. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Region (2021–2032)

Figure 34. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021–2032)

Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021–2032)

Figure 43. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Colombia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021–2032)

Figure 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021–2032)

Figure 49. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Type (2021–2032)

Figure 53. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Type (2021–2032)

Figure 54. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price (US$/Unit) by Type (2021–2032)

Figure 55. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Application (2021–2032)

Figure 56. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Application (2021–2032)

Figure 57. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Price (US$/Unit) by Application (2021–2032)

Figure 58. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Value Chain

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions